The incorporation of novel agents and monoclonal antibody-based therapies into the
treatment of multiple myeloma (MM) has significantly improved long-term patient survival …

Simple Summary During the last two decades, collaborative translational studies utilizing
novel methodologies have dramatically advanced our understanding of multiple myeloma …

Anti-multiple myeloma B cell maturation antigen (BCMA)-specific chimeric antigen receptor
(CAR) T-cell therapies represent a promising treatment strategy with high response rates in …

We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-
specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by …

Antibody–drug conjugates consist of a monoclonal antibody attached to a cytotoxic
therapeutic molecule by a connector. This association allows a highly specific therapy …

Background About 10% of hematologic malignancies are multiple myeloma (MM), an
untreatable cancer. Although lactate and branched-chain amino acids (BCAA) are involved …

Simple Summary Despite the variety of drugs used to treat multiple myeloma and the ever-
lengthening survival times, a recurring problem is that many current drugs affect healthy …

Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now
often treated in the newly diagnosed and relapsed and/or refractory settings with …

TANK-binding kinase 1 (TBK1) is a member of the IKK family and plays a crucial role in the
activation of non-canonical NF-κB signaling and type I interferon responses. The aberrant …

Simple Summary Defining the specificity and biological sequalae induced by receptors
differentiated expressed in multiple myeloma cells are critical for the development of …